Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy alone for Crohn's perianal fistulas (PISA-II): long-term outcomes of an international, multicentre patient preference, randomised controlled trial.
Meima-van Praag EM, Becker MAJ, van Rijn KL, Wasmann KATGM, Stoker J, D'Haens GRAM, Ponsioen CY, Gecse KB, Dijkgraaf MGW, Spinelli A, Danese S, Bemelman WA, Buskens CJ. Meima-van Praag EM, et al. Among authors: gecse kb. EClinicalMedicine. 2023 Jul 5;61:102045. doi: 10.1016/j.eclinm.2023.102045. eCollection 2023 Jul. EClinicalMedicine. 2023. PMID: 37457118 Free PMC article.
Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn's Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo-controlled Trial.
Reinisch W, Colombel JF, D'Haens GR, Rimola J, Masior T, McKevitt M, Ren X, Serone A, Schwartz DA, Gecse KB. Reinisch W, et al. Among authors: gecse kb. J Crohns Colitis. 2024 Jun 3;18(6):864-874. doi: 10.1093/ecco-jcc/jjae003. J Crohns Colitis. 2024. PMID: 38366672 Free PMC article. Clinical Trial.
Perianal Fistulizing Crohn's Disease: Utilizing the TOpClass Classification in Clinical Practice to Provide Targeted Individualized Care.
Hanna LN, Anandabaskaran S, Iqbal N, Geldof J, LeBlanc JF, Dige A, Lundby L, Vermeire S, D'Hoore A, Verstockt B, Bislenghi G, De Looze D, Lobaton T, Van de Putte D, Spinelli A, Carvello M, Danese S, Buskens CJ, Gecse K, Hompes R, Becker M, van der Bilt J, Bemelman W, Sebastian S, Moran G, Lightner AL, Wong SY, Colombel JF, Cohen BL, Holubar S, Ding NS, Behrenbruch C, Sahnan K, Misra R, Lung P, Hart A, Tozer P. Hanna LN, et al. Clin Gastroenterol Hepatol. 2024 Aug 10:S1542-3565(24)00692-X. doi: 10.1016/j.cgh.2024.06.047. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 39134293 Free article. Review.
Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis: Data from the OCTAVE Program.
Dubinsky MC, Armuzzi A, Gecse KB, Ullman T, Bushmakin AG, DiBonaventura M, Cappelleri JC, Connelly SB, Woolcott JC, Salese L. Dubinsky MC, et al. Among authors: gecse kb. Dig Dis. 2023;41(4):604-614. doi: 10.1159/000528788. Epub 2023 Jan 5. Dig Dis. 2023. PMID: 36603566 Free PMC article. Clinical Trial.
Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain.
Allegretti JR, Gecse KB, Chiorean MV, Argollo M, Guo X, Lawendy N, Su C, Mundayat R, Paulissen J, Salese L, Irving PM. Allegretti JR, et al. Among authors: gecse kb. J Gastroenterol Hepatol. 2024 Feb;39(2):264-271. doi: 10.1111/jgh.16386. Epub 2023 Nov 12. J Gastroenterol Hepatol. 2024. PMID: 37953548
104 results